Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

We recently compiled a list of the 10 Companies Echo Friday’s Market Pessimism. In this article, we are going to take a look ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently ...